Skip navigation

News & Updates

BPGbio, Inc. acquired substantially all of the assets of Berg, LLC, and licenses from Berg, LLC the use of the Berg and Berg Health names.

  • November 16, 2023 | Media, News and Updates, Press Releases

    BPGbio Announces Phase 2 BPM31510 Glioblastoma Trial-in-Progress Update at Society for Neuro-Oncology Annual Meeting

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that researchers will present data from an ongoing phase 2 trial study of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM), at the Society for Neuro-Oncology Annual Meeting being held November 16-19, 2023 in Vancouver, Canada.

    read more
  • November 13, 2023 | Media, News and Updates, Press Releases

    Leading AI-Powered Biopharma BPGbio Appoints Kenin Spivak to Board of Directors

    BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors, as an independent director.

    read more
  • November 8, 2023 | Media, News and Updates, Press Releases

    BPGbio Wins 2023 BioTech Breakthrough Award for Therapeutics Platform of The Year

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced it has been recognized with the “Therapeutics Platform Of The Year” award in the third annual BioTech Breakthrough Awards program.

    read more
  • November 7, 2023 | Media, News and Updates, Press Releases

    BPGbio Highlights AI-Developed Late-Stage Therapeutics Assets at 8th Annual INV€$TIVAL Showcase in Partnership with Jefferies

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming INV€$TIVAL Showcase in partnership with Jefferies, being held on November 13, 2023 in London, United Kingdom. 

    read more
  • October 11, 2023 | Media, News and Updates, Press Releases

    BPGbio to Share Updates in Development of Late-Stage AI-Developed Therapeutic Pipeline at the Pharma Partnering Summit

    BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming Pharma Partnering Summit in Boston October 19-20, 2023. At the meeting, BPGbio’s President and CEO, Dr. Niven R. Narain, and Executive Chairman Daniel Elliott will unveil the progress made in advancing their oncology drug candidate BPM31510, currently under investigation for glioblastoma multiforme (GBM) and pancreatic cancer. They will also provide insights into the company’s growing portfolio of AI-discovered therapeutics and diagnostics, identified through the company’s proprietary NAi Interrogative Biology® Platform.

    read more
  • October 3, 2023 | Media, News and Updates, Press Releases

    BPGbio Announces Promising Readout from Phase 2a Trial Evaluating BPM 31510 IV for Pancreatic Cancer

    BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.

    read more